<table>
<thead>
<tr>
<th>Title</th>
<th>Drug Discovery, Development and Deployment: A Report from the 28th Joint Conference of the U.S.-Japan Parasitic Diseases Panels, Baltimore, Maryland, July 1993</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Krogstad, Donald J.; Suzuki, Mamoru; Long, Carole A.; Aoki, Yoshiki; Ishii, Akira; James, Stephanie L.</td>
</tr>
<tr>
<td>Citation</td>
<td>American Journal of Tropical Medicine and Hygiene, 51(4), pp.384-388; 1994</td>
</tr>
<tr>
<td>Issue Date</td>
<td>1994-10</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10069/21859">http://hdl.handle.net/10069/21859</a></td>
</tr>
</tbody>
</table>

Copyright © 1994 by The American Society of Tropical Medicine and Hygiene
DRUG DISCOVERY, DEVELOPMENT AND DEPLOYMENT:
A REPORT FROM THE 28th JOINT CONFERENCE OF THE
U.S.-JAPAN PARASITIC DISEASES PANELS,
BALTIMORE, MARYLAND, JULY 1993*

DONALD J. KROGSTAD, MAMORU SUZUKI, CAROLE A. LONG, YOSHIKI AOKI,
AKIRA ISHII, AND STEPHANIE L. JAMES
Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana; Gunma University
School of Medicine, Maebashi, Japan; Hahnemann University, Philadelphia, Pennsylvania; Nagasaki
University, Nagasaki, Japan; National Institute of Health, Tokyo, Japan; National Institute of
Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Abstract. The 28th Joint Conference of the Parasitic Diseases Panels of the U.S.-Japan
Cooperative Medical Sciences Program held in Baltimore, Maryland focused on current
research within both countries on antiparasitic chemotherapy. This meeting report sum-
marizes presentations of work in progress on antiparasitic drugs currently in use and drugs
under development or in clinical trials, as well as reports on potentially unique parasite
characteristics that may provide targets for development of future therapeutics.

The U.S.-Japan Cooperative Medical Sciences Program was established in 1965 by joint agree-
ment of the President of the United States and the Prime Minister of Japan. The bilateral pro-
gram was organized to promote cooperative research on health problems of recognized impor-
tance in Southeast Asia. Parasitic disease was one of the five original areas selected for collabor-
ative research at that time. Currently, other Panels affiliated with the Program include chol-
era, leprosy, tuberculosis, viral diseases, hepatitis, malnutrition, environmental mutagenesis and
carcinogenesis, and the acquired immunodeficiency syndrome (AIDS). There is also an immu-
noLOGY board intended to provide expertise in this fundamental area of research. The first char-
ter of scientific guidelines to the Parasitic Diseases Panel specified that the research concerns
be confined to schistosomiasis and filariasis, mainly due to their important impact on world
health and economic development. In 1985, however, the guidelines were expanded and re-
search on malaria and other vector-borne parasitic diseases was incorporated into the program.
Annual conferences are held alternatively in the U.S. and Japan. Participants include members of
the U.S. and Japanese Parasitic Diseases Panels as well as other members of the research com-

Drugs in Current Use

Artemisinin. Derivatives of artemisinin are used widely because they are one of the few
effective treatments for multi-drug resistant Plasmodium falciparum malaria. Understanding
the mechanism of artemisinin action may aid in the development of better second generation
drugs. Data presented by Steve Meshnick from the University of Michigan (Figure 1) suggest
that artemisinin has a two step mechanism of action.1-3 First, the drug interacts with intrapara-
sitic heme that catalyzes its conversion into a free radical. Second, the free radical form of the
drug alkylates critical malarial proteins. Evidence for the first step is based on electron spin
resonance spectroscopy and cyclic voltammetry studies that demonstrate that heme can catalyze

384
Drugs Discovery, Development, and Deployment

Malaria target proteins

Figure 1. Proposed two step mechanism of action of artemisinin. First, the drug interacts with intraparasitic heme that catalyzes its conversion into a free radical. Second, the free radical form of the drug alkylates critical malarial proteins.

the opening of the drug's endoperoxide bridge. The fact that iron chelators and free radical scavengers antagonize the antiplasmodial activity of artemisinin in vitro suggests that heme-induced degradation of the endoperoxide bridge may be important in vivo. Evidence for the second alkylation step is based on two observations: 1) alkylation of human serum albumin by artemisinin in vitro, and 2) sodium dodecyl sulfate gel autoradiograms that demonstrate the alkylation of parasite proteins by radiolabeled drug.

Studies presented by Mamoru Suzuki from Gunma University suggest that artemether has a rapid onset of action in vivo in P. falciparum infected Aotus monkeys. Distinct morphologic changes were seen within 2 hr and viable parasites disappeared within 66 hr, although dead intraerythrocytic parasites persisted in the circulation for up to 10 days. Ultrastructural studies showed marked swelling and disruption of the inner membrane of parasite mitochondria within 2 hr. Late changes included clumping of ribosomes and the appearance of electron dense material in the nucleus. Together these observations suggest that mitochondria, which contain many hemoproteins, may be an important target for artemisinin. If this hypothesis is correct, additional information will be required to explain the specificity of artemisinin, i.e., why are the artemisinin concentrations that inhibit parasite growth by damaging their mitochondria not toxic also for mammalian cells at those concentrations?

Dihydrofolate reductase (DHFR) inhibitors. Toshihiro Horii from Osaka University has used a novel approach to study the action of DHFR inhibitors against the P. falciparum DHFR in vitro. To circumvent problems associated with the expression of AT-rich parasite DNA in Escherichia coli, he synthesized an artificial P. falciparum DHFR gene in vitro using characteristic E. coli codons to produce the desired amino acid sequence of the parasite DHFR. Expression of this construct in E. coli yielded ~30% of cell protein as the parasite DHFR. Because most of the parasite DHFR was in aggregates, it did not demonstrate enzymatic activity. However, after solubilization and renaturation, the enzymatic activity, $K_m$, and $V_{max}$ of the parasite DHFR were similar to those of the purified bifunctional P. falciparum DHFR-thymidylate synthase complex, and $K_m$ values were similar to those obtained previously with known inhibitors. This recombinant parasite enzyme is now being used to test candidate DHFR inhibitors in vitro.

Single-dose diethylcarbamazine (DEC) versus ivermectin. In previous studies, DEC has been given in doses of 50–100 mg three times a day for up to 21 days, and has frequently produced severe limiting side effects. In contrast, ivermectin has been given as a single dose every 6–12 months and has had a much lower incidence of side effects. James Kazura from Case Western Reserve University reported a study from Papua New Guinea in which single doses of DEC and ivermectin were compared in persons with bancroftian filariasis. Although the initial decrease in microfilaraemia was greater in the ivermectin group, the results with DEC and ivermectin were similar at 90 and 180 days. Most remarkable was the relative absence of severe side effects with single dose DEC. These results suggest that it may be possible to give DEC as a single dose without the severe side effects observed with 14–21-day regimens, and that single
**Desferrioxamine (DFO).** Data presented by Masamichi Aikawa and Gary Brittenham from Case Western Reserve University suggest that iron-chelating agents such as DFO may offer a new approach to the treatment of cerebral malaria by inhibiting both parasite growth and peroxidant damage to host cells. Parasite growth is inhibited by DFO in vitro, presumably because DFO chelates the iron that the parasite needs to make iron-containing enzymes such as ribonucleotide reductase. This hypothesis is also consistent with morphologic studies that demonstrated nuclear abnormalities as the earliest ultrastructural changes in parasites treated with DFO. Results of a clinical trial indicate that DFO reduced the median duration of deep coma from 68 to 24 hr in children with cerebral malaria, all of whom were treated with quinine, and simultaneously increased the rate of parasite clearance. The variety of iron-chelating agents available raises the possibility that these agents may provide a new class of chemotherapeutic agents for severe and cerebral malaria.

**Amino Acids**

* Figure 2. Proposed mechanism of hemoglobin metabolism in *Plasmodium falciparum*. AH I and II are aspartic hemoglobinases I and II; Cys is the cysteine protease; HP is heme polymerase; Exo is a proposed exopeptidase activity. * indicates the first enzymatic reaction.

Dose DEC may produce antiparasitic effects similar to those obtained with 14–21-day courses of DEC.

**Effect of ivermectin on transmission of onchocerciasis.** Ivermectin markedly reduces the number of microfilariae in the skin of persons with onchocerciasis. In a prospective study carried out in Guatemala, Edward Cupp from the University of Arizona reported that ivermectin also reduced the transmission of onchocerciasis. In a three-year study, four six-monthly treatments with ivermectin reduced both the prevalence and intensity of microfilarial infection in the black fly vector. This change was associated with an 80–100% reduction in transmission as measured by a decrease in the numbers of infective stage larvae in the *Simulium ochraceum*. Repetitive treatment cycles also affected adult worms, increasing the proportions of uniseminated, damaged, and dead female worms in subcutaneous nodules. These results are consistent with a direct drug effect on adult male and female worms in vivo.
of this process that have antiplasmodial activity both in vitro and in vivo.

**Topoisomerase II in trypanosomes.** The mitochondrial (kinetoplastid or k) DNA of the trypanosomes that cause African sleeping sickness contains thousands of interlocked maxi-(~20 kb) and mini-(~1 kb) circles that must undergo many changes during replication and transcription. These reactions are catalyzed by topoisomerases, which are inhibited by a number of drugs in current use as antitumor or antibacterial agents: etoposide, adriamycin, amssacrine, nalidixic acid, and the fluoroquinolones. Data presented by Terry Shapiro from Johns Hopkins University indicate that inhibitors of kinetoplast topoisomerase II act in trypanosomes by stabilizing a cleavable complex between the enzyme and its DNA substrate. Studies in *Trypanosoma equiperdum* demonstrate that etoposide increases the concentration of cleavable complexes between mitochondrial topoisomerase II and minicircle DNA in a time-dependent fashion. The cleavage sites map to positions of importance in minicircle replication. Conventional antitrypanosomal agents such as pentamidine and salmolin also inhibit kinetoplast topoisomerase II activity, and may act against trypanosomes in part by this mechanism. These results support the hypothesis that mitochondrial and nuclear topoisomerase II activities are distinct; they suggest that kinetoplast topoisomerase II enzymes may be important targets in the chemotherapy of trypanosomiasis.

**Thymidylate synthase in Plasmodia.** Previous studies by Pradip Rathod and his colleagues at Catholic University (Washington, DC) have shown that 5-fluoroorotic acid inhibits the growth of *P. falciparum* in vitro and *P. yoelii* in vivo (unpublished data). More recent studies indicate that the concentrations of 5-fluoroorotic acid necessary to inhibit clonal viability of parasites correlate well with those that inhibit thymidylate synthase activity, and thus suggest that the mechanism responsible for this effect is inhibition of the parasite thymidylate synthase.

**Ion channels in Plasmodia.** Patch clamping, which has generally been used with much larger cells such as squid axons, has not been technically feasible previously for either the parasite or its host red blood cell (RBC). After removing the intervening RBC membrane and forming gigaohm seals on the small (3–5 μm) parasite, Desai and his colleagues were able to study transport across the parasitophorous vacuole membrane (PVM), the outer of the two parasite membranes. This approach identified a 140 pS channel on the PVM, which is permeable to both cations and anions, such as lysine+, Tris+, Ca++, Mg++, and glucuronate-. This channel is present at high density and is open more than 98% of the time at the resting potential of the PVM. Together with a new Ca++ pathway in the membrane of the RBC, these studies provide evidence for parasite-induced channels that are potentially unique chemotherapeutic targets. Neither channel is affected by chloroquine, and both are similar in chloroquine-susceptible and -resistant parasites.

**Proteases in schistosomes.** James McKerrow and his colleagues at the University of California in San Francisco have performed a series of studies on rationale drug design using computer modeling of the schistosomal serine protease that cercariae use to cross the skin and infect humans. Based on x-ray diffraction data for similar proteases that have been crystallized, computer modeling was used to create a model of the cercarial serine protease and to examine the interaction with inhibitors using computer graphics. Using this strategy, four of the 40 putative inhibitors identified by computer modeling were found to have Ki values < 100 μM and are therefore being subjected to further study. These studies support the idea that specific inhibitors of parasite enzymes that are effective in vitro and in vivo can be developed with the assistance of computer modeling. Additional studies with peptidomimetic inhibitors have confirmed that cysteine proteases of *Schistosoma mansoni* and *Trypanosoma cruzi* can be selectively inhibited in vitro and in vivo without toxicity at concentrations that interrupt the parasite life cycle.

Financial support: These studies were supported by NIH grants R22 AI-26848 (Steve Meshnick), P01 AI-15351 (James Kazura), AI-29971 (Edward Cupp), AI-10645 (Masamichi Aikawa and Gary Brittenham), R29 AI-31615 (Daniel Goldberg), AI-28855 (Terry Shapiro), AI-26912 (Pradip Rathod), R22 AI-25136 (Donald Krogstad), and AI-20452 (James McKerrow).

Authors' addresses: Tulane School of Public Health and Tropical Medicine, New Orleans, LA 70112. Mamoru Suzuki, Gunma University School of Medicine, Maebashi 371, Japan. Carole A. Long, Hahnemann University, Philadelphia, PA 19102. Yoshiki Aoki, Nagasaki University, Nagasaki 852, Japan. Akira Ishii, National Institute of Health, Tokyo 162, Japan. Ste-
REFERENCES


